Foghorn Therapeutics (FHTX) Total Debt (2019 - 2021)

Foghorn Therapeutics' Total Debt history runs 3 years deep, the most recent figure standing at $19.9 million for Q3 2021.

• In Q3 2021, Total Debt rose 34.64% year-over-year to $19.9 million; the TTM figure through Sep 2021 stood at $19.9 million (up 34.64% YoY), while the FY2020 annual figure was $19.7 million, up 30.06% from the prior year.
• Total Debt for Q3 2021 stood at $19.9 million, roughly flat from $19.8 million in the prior quarter.
• The five-year high for Total Debt was $19.9 million in Q3 2021, with the low at $14.8 million in Q3 2020.
• The 3-year median for Total Debt is $19.7 million (2020), against an average of $18.2 million.
• The sharpest annual moves came in 2020 and 2021: Total Debt soared 30.06% in 2020, then jumped 34.64% in 2021.
• Foghorn Therapeutics' Total Debt stood at $15.1 million in 2019, then soared by 30.06% to $19.7 million in 2020, then gained by 1.32% to $19.9 million in 2021.
• Business Quant data shows FHTX's Total Debt at $19.9 million in Q3 2021, $19.8 million in Q2 2021, and $19.7 million in Q1 2021.